BioHarvest Sciences (NASDAQ:BHST - Get Free Report) is expected to be issuing its Q4 2024 quarterly earnings data before the market opens on Tuesday, April 29th. Analysts expect BioHarvest Sciences to post earnings of ($0.12) per share and revenue of $7.80 million for the quarter.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.05). The business had revenue of $7.17 million during the quarter, compared to the consensus estimate of $7.24 million. On average, analysts expect BioHarvest Sciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
BioHarvest Sciences Stock Down 0.8 %
Shares of BHST traded down $0.05 during mid-day trading on Monday, reaching $6.50. 1,303 shares of the company's stock were exchanged, compared to its average volume of 18,095. The stock's fifty day simple moving average is $5.77. BioHarvest Sciences has a 52-week low of $6.50 and a 52-week high of $7.38. The stock has a market cap of $106.76 million, a PE ratio of -5.20 and a beta of 0.84.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and issued a $14.00 price objective on shares of BioHarvest Sciences in a research note on Tuesday, April 8th.
Read Our Latest Stock Analysis on BioHarvest Sciences
About BioHarvest Sciences
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Featured Stories
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
